Analyst Price Target is GBX 190
▲ +42.86% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ForViva in the last 3 months. The average price target is GBX 190, with a high forecast of GBX 190 and a low forecast of GBX 190. The average price target represents a 42.86% upside from the last price of GBX 133.
Current Consensus is
Moderate Buy
The current consensus among 2 contributing investment analysts is to moderate buy stock in ForViva. This rating has held steady since March 2026, when it changed from a Buy consensus rating.
ForViva
Fevara is an international specialist in livestock supplements.
Fevara’s purpose is to empower farmers in extensive grazing systems with research-proven products that boost profitability, improve resource efficiency and support sustainable agriculture. The Group develops, manufactures and markets research-proven supplements, including feed licks, blocks, bagged minerals, and boluses for cattle, sheep and horses, sold under recognised and trusted brands, including Crystalyx®, Horslic®, Horslyx®, Scotmin Nutrition®, SmartLic®, Tracesure® Advanced and Macal®.
Headquartered in Carlisle, Cumbria, in the UK, Fevara has six manufacturing sites in the UK, US and Brazil with two operational joint ventures in Germany and the US. It serves customers in more than 20 countries through its expansive international distribution and support network.
Fevara has been listed on the London Stock Exchange since 1972. Fevara plc's ticker is "FVA".
For more information, visit: https://www.fevara.com/
Read More
